DARA BioSciences, Inc. (DARA)

Oncology Corporate Profile

Stock Performance

0.8800
0.0000

3 Month Stock History Chart

HQ Location

8601 Six Forks Road, Suite 160
Raleigh, NC 27615

Company Description

DARA is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. DARA sharpened its focus in oncology through its January 2012 acquisition of Oncogenerix, Inc., which holds the exclusive U.S. marketing rights to Soltamox®. Soltamox® is a novel oral liquid formulation of tamoxifen, a product used widely in the treatment and prevention of breast cancer. Soltamox® is the only FDA-approved oral liquid version of tamoxifen and fulfills a vital clinical need for patients who cannot tolerate existing tablet formulations of this drug. DARA plans to begin marketing Soltamox in the U.S. in the third quarter of 2012. DARA is in the process of acquiring a portfolio of additional cancer and cancer-support products for the oncology market, including sterile injectable generic cytotoxic drugs.

Website: http://www.darabiosciences.com/

Brand Generic Indication
Soltamox®tamoxifen citrateSoltamox solution, a nonsteroidal antiestrogen, is for oral administration. Each 5 mL solution contains 10 mg tamoxifen, equivalent to 15.2 mg tamoxifen citrate and the following inactive ingredients: ethanol, glycerol, propylene glycol, sorbitol solution, licorice flavor, aniseed flavor, purified water.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
KRN5500analgesicChemotherapy-induced peripheral neuropathy (CIPN)II

View additional information on product candidates here »

Source: http://www.darabiosciences.com/

Recent News Headlines

8/21/2017 06:19 am

Magic Johnson's HIV Story Offers Hope For Cancer Patients

11/8/2016 06:05 pm

(Forbes) Nov 7, 2016 - Given advances in cancer diagnostics and targeted medications—which have so far mainly been given singularly and in limited combinations—could it be that we’re in a similar position for metastatic cancer in 2016 as for HIV 25 years ago?

MD Anderson Honors Biden With New Cancer Research Chair

11/8/2016 06:05 pm

(ABC News/Assciated Press) Nov 8, 2016 - MD Anderson Cancer Center in Houston, Texas, is creating an endowed chair in recognition of Vice President Joe Biden's late son Beau, a former patient at the hospital.

California's Very Expensive Drug Price Battle: Prop 61 Fight Gets Even Nastier

11/8/2016 06:01 pm

(CNBC) Nov 8, 2016 - If dollars were votes, big pharma would be beating California's controversial drug-price control ballot measure Proposition 61 by a margin of about 7-1.

CMS Official Says Drug Costs Are ‘Unsustainable’ And There Are ‘Too Many’ Bad Actors

11/8/2016 05:44 pm

(STAT/Pharmalot) Nov 7, 2016 - In remarks before the BioPharma Congress, an industry conference that was held last Thursday, the acting administrator for the Centers for Medicare & Medicaid Services slammed drug makers on drug pricing.

U.S. Senate Panel Urges FTC to Launch Antitrust Probe of Mylan

11/8/2016 05:41 pm

(Reuters) Nov 7, 2016 - The U.S. Senate Judiciary Committee urged federal antitrust regulators on Monday to launch a probe into whether EpiPen maker Mylan broke the law by preventing schools from purchasing competing allergy treatments.

Drug Prices to Drop Regardless of U.S. Vote Outcome, Witty Says

11/8/2016 05:39 pm

(Bloomberg) Nov 8, 2016 - Pressure on drug prices in the U.S. will continue regardless of who wins the presidency, the chief executive of the U.K.’s biggest drugmaker said.

White House Issues FAQ Detailing the ACA’s Coverage of Tobacco Cessation Interventions

11/8/2016 05:38 pm

(ASCO in Action) Nov 4, 2016 - On October 27, The White House issued a Frequently Asked Questions (FAQs) document detailing the Affordable Care Act’s (ACA) coverage of tobacco cessation interventions.

FDA Requesting Nominations for Patient Representatives

11/8/2016 05:38 pm

(ASCO in Action) Nov 2, 2016 - The Food and Drug Administration (FDA) is soliciting additional nominations for patient representatives to serve on the Center for Devices and Radiological Health’s (CDRH) Patient Engagement Advisory Committee (PEAC), which provides the FDA with advice on issues relating to medical devices, the regulation of devices, and their use by patients.

American Society of Hematology and Partners Receive Grant to Address Knowledge Gaps in Acute Myeloid Leukemia Care

11/8/2016 05:34 pm

(ASH) Nov 8, 2016 - The American Society of Hematology (ASH) has partnered with several organizations on independent educational programming designed to help address knowledge gaps in the diagnosis and treatment of acute myeloid leukemia (AML).

med fusion Selects N-of-One to Provide Integrated Interpretation for med fusion’s New Hematologic Neoplasm Profiles

11/8/2016 05:33 pm

(N-of-One) Nov 8, 2016 - N-of-One, Inc., a market leader in clinical interpretation with clinical trial matching for molecular tests, today announced that med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, has selected N-of-One to provide integrated interpretation of med fusion’s new HemeSEQ™ profiles for AML, CLL, DLBCL and MPN diseases.

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

11/8/2016 05:30 pm

(Yahoo! Finance) Nov 8, 2016 - Mylan N.V. and Biocon Ltd. today announced submission of Mylan's biologics license application (BLA) for MYL-1401O, a proposed biosimilar trastuzumab, to the U.S. Food and Drug Administration (FDA) through the 351(K) pathway.

Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma

11/8/2016 05:27 pm

(BioMed Reports) Nov 8, 2016 - ECHELON-2 trial represents key component of late-stage clinical development strategy to establish Adcetris as foundation of care for CD30-expressing lymphomas; data from ECHELON-2 phase 3 trial expected in 2017 to 2018 timeframe.

Potential Targeted Therapy Found For Newly Identified Leukemia Subtype With Poor Outcome

11/8/2016 05:26 pm

(St. Jude Children’s) Nov 8, 2016 - An international research team led by St. Jude Children's Research Hospital investigators has uncovered details of a new, high-risk subtype of acute lymphoblastic leukemia (ALL) as well as a possible targeted therapy.

TGen Study Identifies Potential New Drug Targets To Alleviate Pain In Pancreatic Cancer Patients

11/8/2016 05:25 pm

(TGen) Nov 7, 2016 - The Translational Genomics Research Institute (TGen) has discovered potential drug targets to reduce pain in pancreatic cancer patients.

This Common Processed Food Ingredient Causes Cancer in Mice

11/8/2016 05:24 pm

(TIME) Nov 7, 2016 - A new study shows that emulsifiers, which are added to many processed foods, can cause cancer in animals.

UIC Researchers Discover Way To Inhibit Major Cancer Gene

11/8/2016 05:21 pm

(University of Illinois at Chicago) Nov 7, 2016 - RAS mutations found in 30 percent of all cancers.

Low Vitamin D Levels Linked To Increased Risk Of Bladder Cancer

11/8/2016 05:20 pm

(Society for Endocrinology) Nov 8, 2016 - Vitamin D deficiency is associated with an increased risk of developing bladder cancer, according to a systematic review of seven studies presented today at the Society for Endocrinology annual conference in Brighton.

One in Six Women Diagnosed With Breast Cancer Have A Symptom Other Than A Lump

11/8/2016 05:20 pm

(Cancer Research UK/NCRI) Nov 8, 2016 - Around one in six women (17 per cent) diagnosed with breast cancer go to their doctor with a symptom other than a lump – the most commonly reported breast cancer symptom – according to new research presented at the 2016 National Cancer Research Institute (NCRI) Cancer conference in Liverpool.

Checkpoint Blockade Helps Only A Subset Of Patients, Why?

11/8/2016 05:17 pm

(University Of Chicago/ScienceLife) Nov 7, 2016 - Although many cancer patients respond favorably to immunotherapies such as nivolumab and pembrolizumab, most patients do not. Blame for treatment failures is usually attributed to so-called "cold" tumors, those that do not attract T-cell infiltration and may lack key T-cell targets--the mutated proteins known as neoantigens.

Chance of Surviving Childhood Cancer Has Improved — But Survivors’ Overall Health Has Not

11/8/2016 05:17 pm

(Fred Hutch News Service) Nov 7, 2016 - In a large new study of childhood cancer survivors, self-reported health remained constant or declined for patients treated in recent decades.

Childhood Cancer Survivors Living Longer, But Health Suffers

11/8/2016 12:53 pm

(CBS News) Nov 7, 2016 - Thanks to improvements in cancer treatment, childhood cancer survivors are now living longer than ever. But new research suggests that they continue to suffer from health issues down the road.

Novel System To Get Dying Patients An Experimental Cancer Drug Raises Hopes — And Thorny Questions

11/8/2016 12:52 pm

(STAT) Nov 8, 2016 - The drug was still experimental, but clinical trials suggested it could be a lifesaver for patients with a lethal form of blood cancer called multiple myeloma.

FDA Emails Show How Upset Some Officials Were Over The Sarepta Approval

11/7/2016 05:40 pm

(STAT/Pharmalot) Nov 4, 2016 - Newly disclosed emails underscore the extent to which high-ranking US Food and Drug Administration officials were upset with the decision-making process used to approve a controversial Sarepta Therapeutics drug for combating Duchenne muscular dystrophy.

Ionis, Biogen Muscle Drug Succeeds in Second Key Study

11/7/2016 05:40 pm

(Yahoo! Finance/Reuters) Nov 7, 2016 - Biogen Inc and Ionis Pharmaceuticals said a second late-stage study testing their drug for a rare genetic muscular disorder, the leading genetic cause of death in infants, was successful, prompting them to stop the trial early.

Merger Update: Acquisition of DARA BioSciences

12/10/2015 10:02 am

[at noodls] - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION ...

Supplemental Disclosure

12/10/2015 10:02 am

[at noodls] - 19 November 2015 Midatech Pharma PLC ('Midatech' or the 'Company') Midatech Pharma (AIM: MTPH), the specialty pharmaceutical company focused on the development and commercialisation of multiple therapeutic ...

Closing of acquisition

12/10/2015 10:02 am

[at noodls] - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION ...

Merger Update: Amount of New Shares to be Issued

12/10/2015 10:02 am

[at noodls] - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION ...

DARA BioSciences Announces Stockholder Approval of Merger With Midatech

12/2/2015 09:05 pm

[at noodls] - RALEIGH, NC -- (Marketwired) -- 12/02/15 -- DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio ...

DARA BioSciences Announces Stockholder Approval of Merger With Midatech

12/2/2015 09:03 pm

[Marketwired] - DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their ...

DARA BioSciences Announces Third Quarter 2015 Results

11/2/2015 09:04 pm

[at noodls] - Record Revenues for Q3; Company Reaffirms 2015 Full Year Guidance of $3.7 Million in Net Revenues; Company Provides Update on Merger Agreement with Midatech Pharma PLC RALEIGH, NC -- (Marketwired) -- 11/02/15 ...

DARA BioSciences Announces Third Quarter 2015 Results

11/2/2015 09:03 pm

[Marketwired] - DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their ...

DARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015

10/6/2015 12:01 pm

[at noodls] - President and CEO Christopher Clement to Present at 1:30 PM Pacific Time Zone RALEIGH, NC -- (Marketwired) -- 10/06/15 -- DARA BioSciences, Inc. (NASDAQ: DARA)today announced that it will be featured as ...

DARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015

10/6/2015 12:00 pm

[Marketwired] - DARA BioSciences, Inc. today announced that it will be featured as a presenting company at the 2015 Aegis Growth Conference, sponsored by Aegis Capital Corp. The Aegis Growth Conference, which will feature ...

DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush

10/5/2015 12:02 pm

[at noodls] - RALEIGH, NC -- (Marketwired) -- 10/05/15 -- DARA's Salesforce to Launch Oravig Into Oncology Market, While Marketing Partner, Mission Pharmacal, Launches Into the Primary Care Market; Over 28 Million Prescriptions ...

DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush

10/5/2015 12:00 pm

[Marketwired] - DARA BioSciences, Inc. , an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere ...

DARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015

9/23/2015 08:03 pm

[Marketwired] - DARA BioSciences, Inc. , an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their ...

DARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015

9/23/2015 08:03 pm

[at noodls] - DARA's Presentation Is Tuesday, September 29th at 10:00 am EDT RALEIGH, NC -- (Marketwired) -- 09/23/15 -- DARA BioSciences, Inc. (NASDAQ: DARA) , an oncology supportive care pharmaceutical company dedicated ...

DARA BioSciences to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 9, 2015

9/2/2015 08:04 pm

[at noodls] - Live Webcast of DARA's Presentation on Wednesday, September 9th at 9:35 am EDT RALEIGH, NC -- (Marketwired) -- 09/02/15 -- DARA BioSciences, Inc. (NASDAQ: DARA) , an oncology supportive care pharmaceutical ...